Two novel series of 2-amino-3,4-dihydro[1,3,5]triazino[1,2-a]benzimidazoles, and 2-amino-4,4-disubstituted/- spiro[1,3,5]triazino[1,2-a]benzimidazoles were synthesized and evaluated for their in vitro antibacterial activity against Staphylococcus aureus and Escherichia coli. Molecular modeling and docking of the synthesized compounds into enoyl acyl carrier protein reductase (FabI) complexed with its bound inhibitor using Molsoft ICM 3.4-8C program was performed. Among the tested compounds, 2 and 16 were the most potent antibacterial (MIC = 25 ug/ml). Detailed synthesis, spectroscopic and biological data are reported.
Select your language of interest to view the total content in your interested language
Der Pharma Chemica received 15261 citations as per Google Scholar report